Idiopathic Hypersomnia clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

    open to eligible people ages 18-70

    The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.

    at UCSF

  • ALKS 2680 in Subjects With Idiopathic Hypersomnia

    Sorry, in progress, not accepting new patients

    The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets

    at UCSF

Our lead scientists for Idiopathic Hypersomnia research studies include .

Last updated: